A real world, retrospective study of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease
Latest Information Update: 30 Aug 2021
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Aug 2021 New trial record
- 20 Aug 2021 Results published in the Investigational New Drugs.